LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor activity in multiple myeloma and other hematological malignancies. However, its impact on the immune system has ...

本期推荐：研究团队针对HDAC抑制剂(HDACi)在ALK+ ALCL治疗中的矛盾作用展开研究，通过建立NPM::ALK转基因小鼠模型，结合遗传学 ...

在研究结论和讨论部分，研究表明新型嘌呤 - 苯并异羟肟酸化合物，尤其是 4f，在血液恶性肿瘤治疗中展现出了巨大潜力。它不仅能选择性抑制肿瘤细胞活力，还能通过多种机制发挥抗肿瘤作用，并且与维奈托克联合使用可克服耐药性，为治疗耐药血液恶性肿瘤提供了新的治疗策略。这一研究成果为未来 AML 等血液恶性肿瘤的治疗指明了新方向，有望改善患者的治疗效果和预后，具有重要的临床意义 。】 ...

Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...

KLEF Deemed to be University takes pride in announcing a notable breakthrough in the fight against Glioblastoma Multiforme ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity, but additional data from the ELUCIDATE trial in various solid tumors ...

Histone deacetylase 3 (HDAC3) is involved in transcriptional regulation, phosphorylation and the inhibition of tumor suppressor genes. Its upregulation in several types of tumors, such as colorectal, ...

Additionally, the platform supports combination therapies using hedgehog pathway inhibitors alongside HDAC inhibitors to amplify anti-cancer effects. “This new patent for our oncology ...